Composition for Treatment of Damaged Part

Abstract

The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.

1 . A damaged part treatment composition for repairing a damaged part of a target tissue, the composition comprising a stem cell-conditioned medium obtained by culturing stem cells. 
     
     
         2 . The damaged part treatment composition according to  claim 1 , which does not comprise the stem cells. 
     
     
         3 . The damaged part treatment composition according to  claim 1 , wherein the stem cell-conditioned medium comprises at least two cytokines. 
     
     
         4 . The damaged part treatment composition according to  claim 1 , wherein the stem cell-conditioned medium comprises at least two cytokines selected from the group consisting of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and transforming growth factor β (TGF-β). 
     
     
         5 . The damaged part treatment composition according to  claim 1 , wherein the stem cells are somatic stem cells. 
     
     
         6 . The damaged part treatment composition according to  claim 1 , wherein the stem cells are derived from mesenchymal stem cells. 
     
     
         7 . The damaged part treatment composition according to  claim 1 , wherein the stem cells are dental pulp stem cells. 
     
     
         8 . The damaged part treatment composition according to  claim 1 , which does not comprise any serum. 
     
     
         9 . The damaged part treatment composition according to  claim 1 , wherein the treatment of a damaged part comprises treatment of damage to skin, periodontal tissue or bone, treatment of cerebral infarction, or treatment of a central nervous system (CNS) disease. 
     
     
         10 . The damaged part treatment composition according to  claim 1 , wherein the treatment of a damaged part comprises treatment of a CNS disease, and the CNS disease is a disease or disorder selected from the group consisting of a spinal cord injury, a neurodegenerative disorder, degeneration or loss of neuronal cells and a retinal disease involving a neuronal cell disorder. 
     
     
         11 . A method of producing the damaged part treatment composition of  claim 1 , the method comprising the following steps (1) to (3):
 (1) a step of selecting adhesive cells from dental pulp cells;   (2) a step of culturing the adhesive cells; and   (3) a step of collecting a conditioned medium.   
     
     
         12 . The production method according to  claim 11 , further comprising the following step (4):
 (4) a step of subjecting the collected conditioned medium to at least one treatment selected from the group consisting of centrifugation, concentration, solvent substitution, dialysis, freezing, drying, freeze-drying, dilution, desalting and storage.   
     
     
         13 . The production method according to  claim 11 , further comprising one of the following steps (a) or (b):
 (a) a step of checking the collected conditioned medium with respect to the presence or absence of a neurite outgrowth activity in the presence of a nerve regeneration inhibitory substance; or   (b) a step of checking the collected conditioned medium with respect to the presence or absence of an apoptosis inhibitory activity toward neuronal cells.   
     
     
         14 . A damaged part treatment method for repairing a damaged part of a target tissue, the method comprising administering the damaged part treatment composition of  claim 1  to a patient having the target tissue for the damaged part treatment composition, in an amount effective for repairing the damaged part of the target tissue. 
     
     
         15 . The damaged part treatment method according to  claim 14 , wherein the repair of the damaged part is achieved based on an ability of endogenous stem cells. 
     
     
         16 . The damaged part treatment method according to  claim 14 , wherein the damaged part treatment composition is administered by an administration method selected from the group consisting of intravenous administration, intraarterial administration, intraportal administration, intradermal administration, subcutaneous administration, intramuscular administration, intraperitoneal administration and intranasal administration. 
     
     
         17 . A method of treating cerebral infarction comprising administering the damaged part treatment composition of  claim 1  to a cerebral infarction patient, in an amount therapeutically effective for repairing a damaged part of the brain. 
     
     
         18 . The method of treating cerebral infarction according to  claim 17 , wherein the damaged part treatment composition is administered by intranasal administration. 
     
     
         19 . A method of treating a CNS disease comprising administering the damaged part treatment composition of  claim 1  as a CNS disease treatment composition to a CNS disease patient, in a therapeutically effective amount. 
     
     
         20 . The treatment method according to  claim 19 , wherein a dental pulp stem cell is administered to the CNS disease patient simultaneously with, or subsequently to, the administration of the CNS disease treatment composition. 
     
     
         21 . The treatment method according to  claim 20 , wherein the dental pulp stem cell is an undifferentiated dental pulp stem cell that has not been subjected to differentiation-inducing treatment after acquisition thereof, or a differentiation-induced dental pulp stem cell that has been induced to differentiate into a neural cell after acquisition thereof. 
     
     
         22 . The treatment method according to  claim 19 , wherein a pluripotent stem cell that has been induced to differentiate into a neural cell is administered to the CNS disease patient after the administration of the CNS disease treatment composition. 
     
     
         23 . A method of determining whether or not a prepared dental pulp stem cell-conditioned medium is effective as an active ingredient of the CNS disease treatment composition to be employed in the CNS disease treatment method according to  claim 19 , the method comprising at least one of the following steps (a) or (b):
 (a) a step of checking the conditioned medium with respect to the presence or absence of a neurite outgrowth activity in the presence of a nerve regeneration inhibitory substance; or   (b) a step of checking the conditioned medium with respect to the presence or absence of an apoptosis inhibitory activity toward neuronal cells.